{"id":131011,"date":"2026-07-05T15:36:33","date_gmt":"2026-07-05T15:36:33","guid":{"rendered":"https:\/\/www.mymsd.ch\/de\/?page_id=131011"},"modified":"2026-07-05T15:36:35","modified_gmt":"2026-07-05T15:36:35","slug":"keytrudasc","status":"publish","type":"page","link":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytrudasc\/","title":{"rendered":"KFI Keytruda\u00ae SC"},"content":{"rendered":"\n<h1 class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color has-text-color has-link-color wp-elements-2beaf381bebd454464d221f7166a2ce9 mhh-mcn-v1-heading--left mhh-mcn-v1-heading mhh-mcn-v1-heading--0ac200f33c12683a6ccc5dc83546cf9f\" style=\"color:#7c02bb\">Kurzfachinformation KEYTRUDA\u00ae subkutan (Pembrolizumab)<\/h1>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ea09f6f3266ba590041e038feeab7a72\"><strong>KEYTRUDA<sup>\u00ae <\/sup>subkutan:<\/strong> <strong>W: <\/strong>Pembrolizumab. <strong>I: <\/strong><em>Erwachsene<strong>:<\/strong><\/em><strong> <\/strong>Monotherapie indiziert zur Behandlung vonnicht resezierbarem oder metastasiertem Melanom und zur adjuvanten Behandlung bei vollst\u00e4ndig reseziertem Melanom Stadium III; Befristete Zulassung: als Monotherapie zur adjuvanten Behandlung mit vollst\u00e4ndig reseziertem Melanom Stadium IIB oder IIC. <strong>D: <\/strong>KEYTRUDA\u00ae subkutan ausschliesslich f\u00fcr subkutane Anwendung verwenden, nicht intraven\u00f6s, Etikette \u00fcberpr\u00fcfen; KEYTRUDA\u00ae subkutan nicht mit i.v. KEYTRUDA\u00ae ersetzen (andere Dosierung); Umstellung von KEYTRUDA\u00ae subkutan auf i.v. KEYTRUDA\u00ae und umgekehrt m\u00f6glich; subkutane Injektion in Oberschenkel oder Abdomen; Dosis: 395mg alle 3 Wochen oder 790mg alle 6 Wochen, Details siehe Fachinformation; subkutane Injektion etwa 1 Min. (395mg) oder 2 Min. (790mg); Behandlung bis Krankheitsprogression bzw. Auftreten eines Rezidivs oder bis zu unzumutbarer Toxizit\u00e4t; maximale Behandlungsdauer beim adj. Melanom 12 Mt. <strong><em>Weitere Indikationen und die dazugeh\u00f6rigen Dosierungen f\u00fcr Erwachsene entnehmen Sie bitte der Fachinformation.<\/em><\/strong> <strong>KI: <\/strong>\u00dcberempfindlichkeit gegen\u00fcber Wirk-\/Hilfsstoffen. <strong>WH: <\/strong>Immunvermittelte unerw\u00fcnschte Wirkungen: u.a.Pneumonitis, Kolitis, Hepatitis, Nephritis, Endokrinopathien (einschl. Hypophysitis, Typ-1-Diabetes mellitus, Schilddr\u00fcsenfunktionsst\u00f6rungen; bei TNBC Cortisolspiegel \u00fcberwachen), h\u00e4mophagozytische Lymphohistiozytose (HLH), schwere Hautreaktionen (Stevens-Johnson Syndrom, toxische epidermale Nekrolyse, DRESS Syndrom), andere immunvermittelte unerw\u00fcnschte Wirkungen; Patienten mit vorbestehender Autoimmunerkrankung; Transplantation\/ Stammzelltransplantation (HSZT): Graft-versus-Host-Disease (GvHD) und Lebervenenverschlusskrankheit (VOD); Adjuvante Therapie bei Melanom IIB\/IIC und NSCLC IB\/II\/IIIA: OS Analyse ausstehend; Adjuvante Gabe, nach neoadjuvanter Therapie mit zus\u00e4tzlicher Toxizit\u00e4t verbunden; Einfluss auf nachfolgende Gaben von anti-PD-(L)1-basierten Systemtherapien inkl. Resistenzen bei einem Rezidiv wurde nicht untersucht; Erh\u00f6hte Leberenzyme, wenn i.v. KEYTRUDA\u00ae mit Axitinib kombiniert wird (Leberenzyme vor Behandlungsbeginn und w\u00e4hrend der Behandlung \u00fcberwachen); Myokardinfarkt bei Kombination von KEYTRUDA\u00ae mit Lenvatinib bei RCC; Multiples Myelom: erh\u00f6hte Mortalit\u00e4t bei Kombination von i.v. KEYTRUDA\u00ae mit Thalidomid-Analogon und Dexamethason; Kombination mit Trastuzumab bei Magenkarzinom siehe Fachinformation von Trastuzumab; Daten zu Immuntherapie Vorbehandlung bei einzelnen Indikationen liegen nicht vor oder solche Patienten wurden von Studien ausgeschlossen; Infusionsbedingte Reaktionen (einschl. \u00dcberempfindlichkeit und Anaphylaxie); Es wurden Patienten von klin. Studien ausgeschlossen (Details siehe Fachinformation). <strong>DDI: <\/strong>keine bekannt\/ nicht untersucht. <strong>S\/S:<\/strong> nicht empfohlen, Empf\u00e4ngnisverh\u00fctung. <strong>UAW (sehr h\u00e4ufig):<\/strong> Infektionen der Atemwege, Harnwegsinfektion, An\u00e4mie, erniedrigte Neutrophilenzahl, Neutropenie, Thrombozytopenie, Hypothyreose, verminderter Appetit, Hypokali\u00e4mie, erniedrigtes Gewicht, Hypomagnesi\u00e4mie, Schlaflosigkeit, Kopfschmerzen, periphere Neuropathie, Dysgeusie, Hypertonie, Blutungen, Dyspnoe, Husten, Dysphonie, Diarrh\u00f6, Abdominalschmerzen, \u00dcbelkeit, Erbrechen, Obstipation, Lipase erh\u00f6ht, orale Entz\u00fcndungen, Stomatitis, erh\u00f6htes ALT und AST, Hautausschlag, makulopapul\u00e4rer Ausschlag, Pruritus, Alopezie, palmar-plantares Erythrodys\u00e4sthesiesyndrom, Schmerzen der Skelettmuskulatur, Arthralgie, Myositis, Schmerzen in den Extremit\u00e4ten, Proteinurie, Kreatinin im Blut erh\u00f6ht, M\u00fcdigkeit\/Ersch\u00f6pfung, Reaktion an der Injektionsstelle, Asthenie, \u00d6deme, Fieber. <strong>P: <\/strong>1 Durchstechflasche \u00e0 395mg\/2.4ml oder 790mg\/4.8ml. <strong>AK: <\/strong>A. <strong>Z:<\/strong> MSD Merck Sharp &amp; Dohme AG, B\u00fcrgenstrasse 8, 6005 Luzern, Schweiz. (V1.0); CH-KEY-01262.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\" \/>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4617a0b176e4ecd390ac36fd37797640\"><em>Konsultieren Sie bitte vor einer Verschreibung die vollst\u00e4ndige Fachinformation publiziert auf\u00a0<a href=\"https:\/\/www.swissmedicinfo-pro.ch\/ShowText.aspx?textType=FI&amp;lang=DE&amp;authNr=70253\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo-pro.ch<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kurzfachinformation KEYTRUDA\u00ae subkutan (Pembrolizumab) KEYTRUDA\u00ae subkutan: W: Pembrolizumab. I: Erwachsene: Monotherapie indiziert zur Behandlung vonnicht resezierbarem oder metastasiertem Melanom und [&hellip;]<\/p>\n","protected":false},"author":202221,"featured_media":0,"parent":114174,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":1711,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["active","is_keyword","is_date"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[1710],"tags":[1711],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[989],"ga4_page_businessunit":[995],"ga4_page_campaign":[],"ga4_page_content_purpose":[1636],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[1076],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1208],"ga4_page_product":[1502],"ga4_page_region":[1563],"ga4_page_therapeuticarea":[1593],"tx-therapeutic-area":[627],"tx-product":[2380],"tx-pathology":[796],"tx-content-type":[1712],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-131011","page","type-page","status-publish","hentry","category-kfi","tag-kfi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KFI Keytruda\u00ae SC - MyMSD.ch DE<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KFI Keytruda\u00ae SC - MyMSD.ch DE\" \/>\n<meta property=\"og:description\" content=\"Kurzfachinformation KEYTRUDA\u00ae subkutan (Pembrolizumab) KEYTRUDA\u00ae subkutan: W: Pembrolizumab. I: Erwachsene: Monotherapie indiziert zur Behandlung vonnicht resezierbarem oder metastasiertem Melanom und [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytrudasc\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch DE\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-05T15:36:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2186\" \/>\n\t<meta property=\"og:image:height\" content=\"2134\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytrudasc\\\/\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytrudasc\\\/\",\"name\":\"KFI Keytruda\u00ae SC - MyMSD.ch DE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#website\"},\"datePublished\":\"2026-07-05T15:36:33+00:00\",\"dateModified\":\"2026-07-05T15:36:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytrudasc\\\/#breadcrumb\"},\"inLanguage\":\"de-CH\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytrudasc\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/keytrudasc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Product Succinct Statement\",\"item\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/succinctstatement\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"KFI Keytruda\u00ae SC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/\",\"name\":\"MyMSD.ch DE\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-CH\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-CH\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/wp-content\\\/uploads\\\/sites\\\/13\\\/2022\\\/03\\\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png\",\"contentUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/wp-content\\\/uploads\\\/sites\\\/13\\\/2022\\\/03\\\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png\",\"width\":2186,\"height\":2134,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KFI Keytruda\u00ae SC - MyMSD.ch DE","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"de_DE","og_type":"article","og_title":"KFI Keytruda\u00ae SC - MyMSD.ch DE","og_description":"Kurzfachinformation KEYTRUDA\u00ae subkutan (Pembrolizumab) KEYTRUDA\u00ae subkutan: W: Pembrolizumab. I: Erwachsene: Monotherapie indiziert zur Behandlung vonnicht resezierbarem oder metastasiertem Melanom und [&hellip;]","og_url":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytrudasc\/","og_site_name":"MyMSD.ch DE","article_modified_time":"2026-07-05T15:36:35+00:00","og_image":[{"width":2186,"height":2134,"url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytrudasc\/","url":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytrudasc\/","name":"KFI Keytruda\u00ae SC - MyMSD.ch DE","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/de\/#website"},"datePublished":"2026-07-05T15:36:33+00:00","dateModified":"2026-07-05T15:36:35+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytrudasc\/#breadcrumb"},"inLanguage":"de-CH","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytrudasc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/keytrudasc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/de\/"},{"@type":"ListItem","position":2,"name":"Product Succinct Statement","item":"https:\/\/www.mymsd.ch\/de\/succinctstatement\/"},{"@type":"ListItem","position":3,"name":"KFI Keytruda\u00ae SC"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/de\/#website","url":"https:\/\/www.mymsd.ch\/de\/","name":"MyMSD.ch DE","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-CH"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/de\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-CH","@id":"https:\/\/www.mymsd.ch\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png","contentUrl":"https:\/\/www.mymsd.ch\/de\/wp-content\/uploads\/sites\/13\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png","width":2186,"height":2134,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/131011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/users\/202221"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/comments?post=131011"}],"version-history":[{"count":10,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/131011\/revisions"}],"predecessor-version":[{"id":131196,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/131011\/revisions\/131196"}],"up":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/pages\/114174"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/media?parent=131011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/categories?post=131011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tags?post=131011"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_audience?post=131011"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_birn_id?post=131011"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_branding?post=131011"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_businessunit?post=131011"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_campaign?post=131011"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=131011"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=131011"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=131011"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_experience?post=131011"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_indication?post=131011"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_material_intent?post=131011"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_product?post=131011"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_region?post=131011"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=131011"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-therapeutic-area?post=131011"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-product?post=131011"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-pathology?post=131011"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-content-type?post=131011"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/tx-active-ingredient?post=131011"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/access?post=131011"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/user_status?post=131011"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/de\/wp-json\/wp\/v2\/user_role?post=131011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}